Anna Wurtz

Yale Cancer Center — United States

Medicine · Health Sciences

15h-index2.5kcitations198works0.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(173), RNA modifications and cancer(65), Cytokine Signaling Pathways and Interactions(44), Colorectal Cancer Treatments and Studies(36), Cancer Immunotherapy and Biomarkers(22)

Publications198 total

Supplementary Table S4 from Quantitative Protein Expression of Antibody–Drug Conjugate Targets in EGFR Mutated and Wild-type Non–Small Cell Lung Cancer
2025Open Access
Supplementary Figure S4 from Quantitative Protein Expression of Antibody–Drug Conjugate Targets in EGFR Mutated and Wild-type Non–Small Cell Lung Cancer
2025Open Access
Data from Quantitative Protein Expression of Antibody–Drug Conjugate Targets in EGFR Mutated and Wild-type Non–Small Cell Lung Cancer
2025· 1 citedOpen Access
Supplementary Table S3 from Quantitative Protein Expression of Antibody–Drug Conjugate Targets in EGFR Mutated and Wild-type Non–Small Cell Lung Cancer
2025Open Access
Supplementary Data S1-S3 from Quantitative Protein Expression of Antibody–Drug Conjugate Targets in EGFR Mutated and Wild-type Non–Small Cell Lung Cancer
2025Open Access
Supplementary Figure S3 from Quantitative Protein Expression of Antibody–Drug Conjugate Targets in EGFR Mutated and Wild-type Non–Small Cell Lung Cancer
2025Open Access
Supplementary Table S1 from Quantitative Protein Expression of Antibody–Drug Conjugate Targets in EGFR Mutated and Wild-type Non–Small Cell Lung Cancer
2025Open Access
Supplementary Figure S2 from Quantitative Protein Expression of Antibody–Drug Conjugate Targets in EGFR Mutated and Wild-type Non–Small Cell Lung Cancer
2025Open Access
Supplementary Figure S5 from Quantitative Protein Expression of Antibody–Drug Conjugate Targets in EGFR Mutated and Wild-type Non–Small Cell Lung Cancer
2025Open Access
Supplementary Table S2 from Quantitative Protein Expression of Antibody–Drug Conjugate Targets in EGFR Mutated and Wild-type Non–Small Cell Lung Cancer
2025Open Access
Supplementary Figure S1 from Quantitative Protein Expression of Antibody–Drug Conjugate Targets in EGFR Mutated and Wild-type Non–Small Cell Lung Cancer
2025Open Access
Clinical features associated with an exceptional response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology·2025
Quantitative Protein Expression of Antibody–Drug Conjugate Targets in EGFR Mutated and Wild-type Non–Small Cell Lung Cancer
Clinical Cancer Research·2025· 3 citedOpen Access
Supplementary Figure S3 from Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations
2024Open Access
Data from Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations
2024Open Access
Supplementary Figure S1 from Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations
2024Open Access
Supplementary Table S1 from Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations
2024Open Access
Supplementary Figure S2 from Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations
2024Open Access
Supplementary Figure S1 from Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations
2024Open Access
Supplementary Figure S3 from Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations
2024Open Access
page 1 of 10Next →

Frequent Co-authors

Katerina Politi(44), Scott Gettinger(35), Zenta Walther(28), Sarah B. Goldberg(24), Jungmin Choi(20), Mary Ann Melnick(20), Guoping Cai(17), Robert Homer(17), Fernando J. de Miguel(12), Andrew Xiao(12), Qin Yan(12), Don X. Nguyen(12), Helena A. Yu(11), Bomiao Hu(11), Marc Wiesehöfer(11), Zongzhi Liu(11), Lok-Hei Chan(11), Anna Arnal Estape(11), Dejian Zhao(11), Francesc López‐Giráldez(11)